The findings show that not only is neoadjuvant chemoimmunotherapy a superior treatment option in NSCLC across various clinical end points, but it also offers a potential breakthrough for patients ...

For patients with locally advanced prostate cancer, neoadjuvant chemohormonal therapy (NCHT) is beneficial for biochemical progression-free survival (bPFS), according to a study published online May 1 ...

Survival according to treatment group and complete pathologic response (pT0) in patients treated with either neoadjuvant MVAC and cystectomy or cystectomy alone. Hazard ratios for subgroups ...

In a recent multi-center study published in the Journal of the National Cancer Institute, researchers examined the effects of neoadjuvant chemotherapy (NAC) on patients suffering from locally ...

Neoadjuvant immunotherapy (pembrolizumab) may offer better pathologic response than neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer undergoing radical cystectomy.

4 Pathologic complete response, however, cannot serve as a criterion to select patient for neoadjuvant chemotherapy as it can only be assessed for after such therapy. The Complexity INdex in SARComas ...

Uncertainties and Challenges in the Future of Neoadjuvant Immunotherapy in ER+/HER2– Breast Cancer In a trial-level meta-analysis of neoadjuvant trials, the ORs of pCR rate did not correlate with the ...

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update, and announced financial ...

A new study suggested that adding nivolumab to neoadjuvant treatment improves outcomes in patients with borderline resectable ...

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of ...

Tina Cascone, MD, PhD, discusses who was included in the phase 3 CheckMate-77T trial and the key end points of the study.